Laquinimod

DB06685InvestigationalSmall molecule

Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries. It is currently under development in phase III trials for treatment of multiple sclerosis as an... It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally.

Chemical structure of Laquinimod
Primary indication
Investigated for use/treatment in multiple sclerosis.Curator reviewed
Formula / weight
C19H17ClN2O3 · 356.81 g/mol (avg)
Code names
ABR-215062

Resolves to

Compound
UNII908SY76S4GCAS248281-84-7ChEMBLCHEMBL66092ChEBI134738PubChem54677946
Clinical / RWD
ATCN07XX10
Structure
InChIKeyGKWPCEFFIHSJOE-UHFFFAOYSA-NSMILESCCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1
Targets
Q04864RELQ01201RELBQ04206RELAQ00653NFKB2P19838NFKB1P19875CXCL2

What you can answer from here — as of September 23, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
109Drug interactionsStructured to mechanism, not free text
Sign in
14Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 6 drug categories
Sign in
11+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Laquinimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In